PathwayPrism, one of the first pathway-analysis software products to hit the market, has had a tangled history over the last few years, but now it's back in the hands of one of its original developers, who believes that there is still plenty of opportunity for the technology.

Scott Lett, CEO of the BioAnalytics Group, told BioInform this week that his firm is now developing a new version of PathwayPrism, which he helped develop at Physiome Sciences before the company was acquired by Predix Pharmaceuticals in 2003 [BioInform 09-01-03].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.